» Articles » PMID: 29085508

Triptolide Induces DNA Breaks, Activates Caspase-3-dependent Apoptosis and Sensitizes B-cell Lymphoma to Poly(ADP-ribose) Polymerase 1 and Phosphoinositide 3-kinase Inhibitors

Overview
Journal Oncol Lett
Specialty Oncology
Date 2017 Nov 1
PMID 29085508
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Triptolide is the primary compound isolated from , which has been reported to inhibit nucleotide excision repair as well as exhibit anti-inflammatory and antitumor activities. However, the action of triptolide in DNA breaks remains unknown. The present study investigated the effects of triptolide in the induction of DNA breaks and apoptosis in a murine B-cell lymphoma cell line, CH12F3. An MTT assay revealed that X-ray repair cross-complementing protein 1 (XRCC1) CH12F3 cells were more sensitive to 6 nM triptolide compared with the wild-type CH12F3 cells, which suggests that low levels of triptolide induce DNA breaks in a manner that is dependent on the XRCC1-mediated repair pathway. Flow cytometric analysis identified that 50 nM triptolide increased the phospho-histone H2AX level, demonstrating that triptolide induces double-strand breaks. Western blot analysis revealed that triptolide up-regulated Rad51 and nuclear proliferating cell nuclear antigen. Annexin V/propidium iodide staining identified that triptolide promoted apoptosis and western blot analysis confirmed that triptolide activated caspase-3-dependent apoptosis. The results of the present study also demonstrated that 5 nM triptolide sensitized CH12F3 lymphoma cells to poly(ADP-ribose) polymerase 1 and phosphoinositide 3-kinase inhibitors, suggesting that triptolide may be a potent antitumor drug for sensitizing lymphoma cells to chemotherapeutic agents.

Citing Articles

Targeting the DNA damage response (DDR) of cancer cells with natural compounds derived from and other plants.

Choi S, Shin M, Kim W J Ginseng Res. 2025; 49(1):1-11.

PMID: 39872282 PMC: 11764321. DOI: 10.1016/j.jgr.2024.04.001.


Exploring the Therapeutic Potential of Triptonide in Salivary Adenoid Cystic Carcinoma: A Comprehensive Approach Involving Network Pharmacology and Experimental Validation.

Geng S, Chen L, Lin W, Wan F, Le Z, Hu W Curr Pharm Des. 2024; 30(29):2276-2289.

PMID: 38910414 DOI: 10.2174/0113816128315277240610052453.


Triptolide Shows High Sensitivity and Low Toxicity Against Acute Myeloid Leukemia Cell Lines Through Inhibiting WSTF-RNAPII Complex.

Kang D, Liu Y, Song Y, Fang B, Zhang Q, Hu L Front Oncol. 2022; 12:811850.

PMID: 35251980 PMC: 8888427. DOI: 10.3389/fonc.2022.811850.


Natural Compounds That Target DNA Repair Pathways and Their Therapeutic Potential to Counteract Cancer Cells.

Lagunas-Rangel F, Bermudez-Cruz R Front Oncol. 2020; 10:598174.

PMID: 33330091 PMC: 7710985. DOI: 10.3389/fonc.2020.598174.


Discovery of potential targets of Triptolide through inverse docking in ovarian cancer cells.

Wu Q, Bao G, Pan Y, Qian X, Gao F PeerJ. 2020; 8:e8620.

PMID: 32219016 PMC: 7085293. DOI: 10.7717/peerj.8620.

References
1.
Liu J, Shen M, Yue Z, Yang Z, Wang M, Li C . Triptolide inhibits colon-rectal cancer cells proliferation by induction of G1 phase arrest through upregulation of p21. Phytomedicine. 2012; 19(8-9):756-62. DOI: 10.1016/j.phymed.2012.02.014. View

2.
Caldecott K, McKeown C, Tucker J, Ljungquist S, Thompson L . An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol. 1994; 14(1):68-76. PMC: 358357. DOI: 10.1128/mcb.14.1.68-76.1994. View

3.
Jao H, Yu F, Yu C, Chang S, Liu K, Liao C . Suppression of the migration and invasion is mediated by triptolide in B16F10 mouse melanoma cells through the NF-kappaB-dependent pathway. Environ Toxicol. 2015; 31(12):1974-1984. DOI: 10.1002/tox.22198. View

4.
Critchlow S, Bowater R, Jackson S . Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr Biol. 1997; 7(8):588-98. DOI: 10.1016/s0960-9822(06)00258-2. View

5.
Damato V, Rosa R, DAmato C, Formisano L, Marciano R, Nappi L . The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. Br J Cancer. 2014; 110(12):2887-95. PMC: 4056056. DOI: 10.1038/bjc.2014.241. View